The study, led by clinicians within a lung cancer screening program directed by Julie Barta, MD, an associate professor at Sidney Kimmel Medical College, focused on women between the ages of 50 and 75 who were current smokers or had a significant smoking history. Current guidelines call for people in this group to undergo an annual chest computed tomography scan to look for early signs of lung disease, including lung cancer, which remains the leading cause of cancer death in the United States. But the same population carries elevated risk for other malignancies as well. Smoking is a well-established risk factor across many cancer types, and as Meghan Maceyko, MD, a fourth-year general surgery resident and one of the researchers, puts it plainly: smoking is a risk factor in all cancers. For older women with substantial smoking histories, that includes breast cancer, one of the most common diagnoses in this age group and one for which mammography screening has repeatedly been shown to save lives when tumors are caught early.

To understand how well these women were keeping up with breast cancer screening, the team took a retrospective look at their electronic health records. The question was simple: had each woman received a mammogram in the two years before her lung cancer screening scan, a window consistent with standard recommendations for breast cancer screening in this age range? The records allowed the researchers to go beyond a single adherence number and examine patient characteristics associated with being overdue. What emerged was a pattern that clinicians who work in preventive care will recognize with frustration. Women with a greater smoking history were more likely to be overdue for mammography, and so were women who had previously been diagnosed with cancer.

That second finding is the one that gives the study its urgency. Patients with a prior cancer diagnosis are, by definition, among the highest-risk people in any screening population. They have already faced one malignancy, they are monitored closely for recurrence, and many are at increased risk for secondary cancers, whether because of shared risk factors such as smoking, the late effects of treatment, or genetic susceptibility. Yet the Jefferson analysis suggests that these very patients were among the least likely to be current on breast cancer screening. In other words, the women who stood to benefit most from a routine mammogram were the ones least likely to be getting one. The researchers describe this as a critical gap in preventive care, and the phrase is not an exaggeration. Screening programs are designed to concentrate resources where risk is highest, so an inverse relationship between risk and adherence signals that something in the delivery system is failing the patients who need it most.

Why might the highest-risk patients be the least well screened? The study did not set out to answer that question directly, but several plausible mechanisms fit the data. Patients with extensive smoking histories often carry a heavier burden of chronic disease overall, from cardiovascular disease to chronic obstructive pulmonary disease, and their medical visits may be dominated by the management of immediate symptoms rather than preventive planning. A prior cancer diagnosis can complicate the picture further. Survivorship care is frequently fragmented between oncologists and primary care providers, and responsibility for routine screening can fall into the space between them. Some survivors may also experience avoidance or anxiety around testing that recalls their original diagnosis. Whatever the individual explanations, the aggregate result is the same: the patients with the most to gain from screening are the ones most likely to slip past it unnoticed.

The proposed remedy is deliberately modest in its technical demands. Rather than building new programs or requiring additional visits, the researchers suggest embedding a breast cancer screening prompt into the intake process that lung screening patients already complete. For medical centers that operate lung cancer screening programs, such as Jefferson Health, the infrastructure is already in place. Patients are scheduled, registered, asked structured questions about their health, and seen by nursing staff before their scan. The next step, Maceyko notes, is simply to choose an easy and effective prompt. That could take the form of a pop-up reminder embedded in the screening questionnaire, or a single added question posed by the intake nurse. Either way, the intervention targets the moment of maximum engagement, when a high-risk patient is physically present and the health system has her attention.

The elegance of this approach lies in what it does not require. It does not require new imaging equipment, additional staffing, or a separate outreach campaign with mailings and phone calls. It does not require patients to navigate a new appointment or a new department. It piggybacks on a visit that already exists for a population that is already identified as high-risk by virtue of enrollment in lung screening. In implementation science, this kind of design is often described as leveraging existing touchpoints, and it is one of the most reliable ways to improve adherence at scale. A prompt that takes seconds to deliver can convert an otherwise missed screening into a completed one, particularly when it is paired with a clear pathway for scheduling the mammogram before the patient leaves.

The implications extend well beyond the pairing of chest CT and mammography. The same logic applies to any setting in which patients at elevated risk for one condition are seen for the surveillance of another. A patient arriving for colonoscopy could be asked about cervical screening; a patient in a dermatology surveillance program could be prompted about breast or colorectal testing. The researchers point out that further work in this area may open additional avenues for improving adherence, including prompts about other cancer screenings and the creation of pathways for electronic health records to automatically flag overdue tests. Modern EHR systems already track due dates for preventive services, but turning that data into action at the point of care remains inconsistent. A flag that surfaces during check-in, or a question scripted into the intake workflow, closes the distance between knowing that a test is overdue and actually getting it done.

There is also a broader lesson in the study’s central paradox. Health systems tend to assume that patients who are engaged enough to participate in one specialized screening program are likely to be current on their other preventive care, but the Jefferson data show that this assumption cannot be relied upon. Enrollment in lung screening identifies a high-risk population, yet within that population, adherence to mammography varies in ways that track with smoking history and cancer history rather than with engagement. Screening status for one test is simply not a reliable proxy for screening status across the board. That is precisely why an explicit prompt matters: it replaces an assumption with a question, and a question asked at the right moment can be answered, acted upon, and documented.

For the women at the center of the study, the stakes are concrete. Lung cancer screening exists because early detection changes outcomes in a disease that is usually found too late; mammography exists for the same reason in breast cancer. A patient who receives both screenings on schedule is protected twice, at a combined cost of two imaging appointments a year. If a pop-up reminder or an extra intake question can move even a fraction of overdue patients into compliance, the intervention will have earned its place in the workflow. The Jefferson team’s contribution is to show where the gap lies, who falls into it, and how small the fix could be. The next phase of research will determine which prompts work best and how far the principle can be extended, but the direction is already clear: the most efficient place to catch a missed screening is at the appointment the patient was already going to attend.

Subject of Research: Breast cancer screening adherence among women enrolled in a lung cancer screening program

Article Title: Boosting cancer screenings in high-risk groups

Article References: Boosting cancer screenings in high-risk groups. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: lung cancer screening, mammography, breast cancer, smoking, preventive care, screening adherence, electronic health records, Thomas Jefferson University, high-risk patients, cancer survivors, chest CT, health care intervention

Oral squamous cell carcinoma represents the predominant category of head and neck cancers worldwide, notorious for its aggressive progression and substantial morbidity. While the association between HBV—a virus primarily known for its hepatic complications—and liver cancers is well-documented, this study uniquely highlights HBV’s clinical implications beyond the liver, particularly its influence on extrahepatic malignancies like OSCC. The researchers embarked on a mission to decode whether active HBV infection affects cancer advancement or patient survival, a question that has remained largely unexplored until now.

The team utilized hepatitis B surface antigen (HBsAg) seropositivity as a biomarker to determine active HBV infection status among OSCC patients. Through rigorous propensity score matching based on variables including age, sex, and cancer staging, the study meticulously compared clinical outcomes between HBV-positive and HBV-negative cohorts. Such methodological precision lends robustness to their conclusions, minimizing confounding effects and allowing a clearer understanding of HBV’s role in OSCC prognosis.

Remarkably, the prevalence of HBV infection within this cohort stood at 12%, with the HBsAg-positive group predominantly comprising younger patients under 60 years old. This demographic nuance may reflect epidemiological trends of HBV exposure but also raises questions about viral oncogenesis accelerating cancer evolution in younger populations. The age distribution itself could have profound implications for screening protocols and tailored therapeutic approaches in clinical practice.

Survival analyses revealed that patients harboring HBV exhibited significantly diminished overall survival (OS) and disease-free survival (DFS) rates at five years post-diagnosis compared to their HBV-negative counterparts. This disparity was especially pronounced among individuals presenting with advanced-stage disease and cervical lymph node metastasis, emphasizing the compounded risks HBV infection introduces to an already precarious prognosis. These findings highlight HBV as a formidable adversary in the fight against OSCC, influencing not only cancer biology but also clinical outcomes.

Further, multivariate analyses established that the absence of HBsAg—indicative of no active HBV infection—served as an independent protective prognostic factor, halving the hazard ratio for mortality and reducing disease recurrence risks. This statistical evidence crystalizes the prognostic significance of HBV status in OSCC, suggesting that viral infection status should be integrated into routine oncological assessments, much like traditional staging parameters.

One of the study’s most intriguing revelations pertains to the role of elective neck dissection in OSCC patients with concurrent HBV infection. Neck dissection, a surgical procedure aimed at removing potentially affected lymphatic tissues, emerged as an independent protective factor contributing to improved survival outcomes in this subgroup. This insight not only informs surgical decision-making but also prompts reevaluation of treatment algorithms where viral infection complicates the oncologic landscape.

Conversely, established risk factors such as depth of invasion (DOI) and pathological nodal status continued to predict adverse prognosis, reaffirming their critical place in the pathology of OSCC. The interplay of these tumor characteristics with viral infection underscores a multifactorial framework determining patient outcomes, where viral, pathological, and therapeutic variables intersect to shape survival trajectories.

The implications of these findings extend beyond clinical prognostication. The authors advocate for routine HBV screening prior to initiating tumor therapies in OSCC patients, a recommendation grounded in the dual imperative of optimizing cancer outcomes and preventing HBV reactivation. Given that cancer treatments, especially chemotherapy and immunotherapy, can precipitate viral reactivation with potentially fatal consequences, pre-treatment viral assessment and prophylactic antiviral therapy emerge as indispensable components of comprehensive patient management.

Moreover, the study underscores the potential benefits of antiviral prophylaxis and systematic serological monitoring throughout the cancer treatment continuum. By curtailing viral activity, clinicians may not only safeguard liver function but also potentially modulate tumor behavior indirectly influenced by chronic infection and inflammation. This integrated care model exemplifies precision medicine’s promise in tailoring interventions based on viral and tumor biology.

Intriguingly, the study’s retrospective design encompassing a large patient population over ten years adds significant weight to the clinical correlations observed, yet it simultaneously encourages future prospective studies and mechanistic investigations. Understanding how HBV mechanistically influences OSCC tumorigenesis, immune evasion, or microenvironment alterations could pave the way for novel therapeutic targets, potentially improving survival in this vulnerable patient population.

Furthermore, these data raise important public health considerations, particularly in HBV-endemic regions where OSCC incidence is also high. Integrating viral screening into head and neck cancer programs could lead to earlier detection of at-risk patients and adaptive treatment strategies, ultimately mitigating the compounded burden of OSCC and HBV co-morbidity. Such multidisciplinary approaches are vital to reducing cancer mortality on a global scale.

While the precise biological pathways underpinning HBV’s impact on OSCC remain to be fully elucidated, the study fortifies the hypothesis that chronic viral infection modulates carcinogenesis far beyond the liver. It may invoke chronic inflammatory states, immune dysregulation, and direct oncogenic viral effects, all of which could influence tumor progression and response to therapy. These emerging concepts invite a paradigm shift in how oncologists and virologists collaborate.

In conclusion, this comprehensive analysis offers compelling evidence that hepatitis B virus infection constitutes a critical prognostic marker for oral squamous cell carcinoma, influencing survival outcomes significantly. The findings advocate for routine HBV screening, vigilant serological monitoring, and consideration of elective neck dissection in HBV-positive early-stage OSCC patients. These insights not only enhance our understanding of viral-oncologic interplay but also hold tangible implications for optimizing patient-tailored therapeutic strategies and improving survival statistics.

As cancer research continues to unravel the intricate nexus between infections and malignancies, studies like this illuminate the path toward integrative, multidisciplinary cancer care. They reinforce the necessity of considering viral status in oncologic paradigms, potentially reshaping treatment standards and offering new hope to patients worldwide grappling with the dual challenges of cancer and chronic infection.

Subject of Research: Clinical correlation and survival analysis of hepatitis B virus infection in oral squamous cell carcinoma patients.

Article Title: Clinical correlation and survival analysis of hepatitis B virus infection in oral squamous cell carcinoma: a retrospective study of 1373 patients.

Article References:
Tan, R., Zhu, Y., Chen, Z. et al. Clinical correlation and survival analysis of hepatitis B virus infection in oral squamous cell carcinoma: a retrospective study of 1373 patients. BMC Cancer 25, 801 (2025). https://doi.org/10.1186/s12885-025-14188-8

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14188-8